21:32:08 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-03-15 Ordinarie utdelning ALK B 0.00 DKK
2024-03-14 Årsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-09 Kvartalsrapport 2023-Q1
2023-03-20 Ordinarie utdelning ALK B 0.00 DKK
2023-02-03 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-03-28 Split ALK B 1:20
2022-03-17 Ordinarie utdelning ALK B 0.00 DKK
2022-03-16 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-05-05 Kvartalsrapport 2021-Q1
2021-03-19 Ordinarie utdelning ALK B 0.00 DKK
2021-03-18 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-03-12 Ordinarie utdelning ALK B 0.00 DKK
2020-03-11 Årsstämma 2020
2020-02-05 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-13 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-03-14 Ordinarie utdelning ALK B 0.00 DKK
2019-03-13 Årsstämma 2019
2019-02-07 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-04 Kvartalsrapport 2018-Q1
2018-03-13 Ordinarie utdelning ALK B 0.00 DKK
2018-03-12 Årsstämma 2018
2018-02-06 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-16 Ordinarie utdelning ALK B 5.00 DKK
2017-03-15 Årsstämma 2017
2017-02-07 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-16 Kvartalsrapport 2016-Q2
2016-05-04 Kvartalsrapport 2016-Q1
2016-03-11 Ordinarie utdelning ALK B 5.00 DKK
2016-03-10 Årsstämma 2016
2016-02-09 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-05 Kvartalsrapport 2015-Q1
2015-03-13 Ordinarie utdelning ALK B 5.00 DKK
2015-03-12 Årsstämma 2015
2015-02-09 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-03-13 Ordinarie utdelning ALK B 5.00 DKK
2014-03-12 Årsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-11-08 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-03 Kvartalsrapport 2013-Q1
2013-03-13 Ordinarie utdelning ALK B 5.00 DKK
2013-03-12 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-11-12 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-03-28 Ordinarie utdelning ALK B 5.00 DKK
2012-03-27 Årsstämma 2012
2012-02-22 Bokslutskommuniké 2011
2011-11-11 Kvartalsrapport 2011-Q3
2011-08-16 Kvartalsrapport 2011-Q2
2011-05-10 Kvartalsrapport 2011-Q1
2011-04-04 Ordinarie utdelning ALK B 5.00 DKK
2011-04-01 Årsstämma 2011
2010-03-29 Ordinarie utdelning ALK B 5.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
AlK-Abelló är verksamma inom läkemedelsbranschen. Bolaget är en utvecklare av allergi- och immunterapi. Verksamhet innehas på global nivå och produkterna säljs både som vaccin och i tablettform. En stor del av verksamheten fokuserar mot forskning och utveckling inom nämnt arbetsområde, där bolaget aktivt arbetar med diagnostisering och behandling av återkommande allergibesvär. Bolaget grundades 1923 och har sitt huvudkontor i Hørsholm.
2022-06-27 12:44:59

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):

  • ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
  • The trial marks the formal start of clinical development of the peanut SLIT-tablet which uses same technology as ALK’s SLIT-tablets for respiratory allergies.

        
ALK announced today that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy. Under the name Alliance, the trial will be conducted in North America and will assess the tolerability and safety of an up-dosing regimen with a once-daily peanut SLIT-tablet.

ALK first announced its intention to establish a presence in the treatment of food allergies in early 2021. Initiation of the Alliance Phase I trial follows the successful completion of a feasibility study in late-2021, which confirmed that the same technology used in ALK’s SLIT-tablets for respiratory allergies, was also suitable for use in the peanut SLIT-tablet.

In all, approximately 100 adults, adolescents and children, who have a confirmed peanut allergy, will participate in the trial, which is expected to involve up to 15 centres. Screening of patients will begin soon and, and the trial is scheduled to complete in 2023.

Henrik Jacobi, ALK’s Executive Vice President of R&D, said: Peanut allergy is an area of significant unmet medical need, and ALK is committed to seeking new solutions that address the needs of people who live with this potentially life-threatening condition. We will use our profound R&D expertise, and the extensive experience gained in the clinical development of our SLIT-tablets for respiratory allergies, to develop a potentially valuable new treatment option for prescribers and their peanut-allergic patients.”

The Alliance trial is a Phase I, open-label, dose-escalation, multi-centre trial, with participants screened via double-blind, placebo-controlled food challenges to confirm their peanut allergy. There will be two stages to the trial. The first is designed to determine the starting dose of the up-dosing regimen, and the second to assess the tolerability of the up-dosing regimen. Further objectives are to assess the safety of the peanut SLIT-tablet and, in the second stage, to gather early data on its biological action. The trial will consist of up to 10 cohorts, split evenly between the two stages of the trial.

In the USA, peanut allergy affects up to 1.5 million children and adolescents aged 4-17, while in Europe, around 1 million children and adolescents are affected by this potentially life-threatening condition. The disease often presents in early childhood, and can last a lifetime. For some of these patients, allergy immunotherapy may become a relevant treatment option with the potential to improve quality of life, both for them and their families.

Alongside its work to develop a peanut SLIT-tablet, ALK is also further developing its range of respiratory SLIT-tablets in order to extend their coverage to children and adolescents in more markets, and is currently conducting Phase III paediatric trials of its house dust mite and tree pollen SLIT-tablets.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.